The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c of 7.0% or below. Up to 72.3% lost 5% or more of their body weight. The data was published in The Lancet and presented live by Dr. Vanita Aroda of Mass General Brigham.

Pharma analysts are already penciling in billions. The Wall Street version is simple: better pill, lower blood
sugar, problem solved.

It isn’t.

What ADA 2026 Actually Showed

The trial — SOLSTICE — randomized adults with Type 2 diabetes to elecoglipron or placebo for 26 weeks. The headline number is the 89.6% figure. Here is what the press releases skip: the endpoint was A1c ≤ 7.0%. That is the ADA’s own target for diabetes management. It is the threshold that defines controlled diabetes — not the absence of diabetes.

A patient at 6.9% A1c is still diabetic. They are just better medicated.

The SOLSTICE data is genuinely impressive by the standard of glycemic control. Reported in The Lancet and described in Science Daily’s coverage of the ADA 2026 presentation, the safety profile matched the GLP-1 class — mostly GI side effects, mostly tolerable. Lilly is positioning elecoglipron as a less burdensome alternative to oral semaglutide, which currently must be taken on an empty stomach with a 30-minute wait before food or drink. If approved, this would be the first oral GLP-1 without the fasting constraint.

That is real progress. It is not reversal.

The Question Nobody at ADA Asked

Here is the framing problem. Every trial endpoint in this category — elecoglipron, oral semaglutide, Mounjaro, Zepbound, retatrutide — uses A1c ≤ 7% as the success line. Seven percent is the medical world’s definition of “well-controlled diabetes.” The number is a management target, set decades ago when the only tools were metformin, sulfonylureas, and insulin.

It was never a reversal target.

If you are a Type 2 diabetic reading this, ask yourself one question: do you want your diabetes controlled, or do you want it gone?

There is a difference. A1c below 5.7% off all medication is reversal. Below 5.7% on a GLP-1 is still diabetes — the medication is what is keeping you there. Stop the drug, the number climbs back. The trial endpoints make this distinction invisible, because the entire conversation is about staying on the drug, not coming off it.

Why Reversal Is Possible — and What the Mainstream Press Will Not Print

The DiRECT trial — a landmark study out of Newcastle University by Professor Roy Taylor — proved Type 2 diabetes reversal is achievable through structured weight loss and caloric restriction. Patients came off insulin and oral medications and held an average A1c below the diabetic threshold at 12 months. The mechanism is well understood: lose the excess visceral fat off the pancreas and liver, and beta-cell function returns.

GLP-1 drugs accelerate weight loss. They do not reverse the underlying metabolic dysfunction. They do not restore pancreatic function. They do not get you off medication.

At Diabetes Reversal Group, we have delivered an average reversal A1c of 4.7% in 4.5 months across our patient population using the only patented system in the world proven to reverse Type 2 diabetes (US patent granted September 2020). Our patient outcomes tell the story the SOLSTICE trial cannot: people off all medications, A1c in the non-diabetic range, no injections, no daily pills.

That is the standard every new GLP-1 should be measured against. None of them clear it.

What to Do With This News

If you are starting a GLP-1 — or being pressured to start one — understand what the trial you are reading about actually delivered. Better blood sugar control while on medication is not reversal. It is a slower path to the same destination

Reversal is possible. The research proves it. The patents exist. The patients are walking proof.

Watch the free webinar at Diabetes Reversal Group to see how the system works — no GLP-1, no insulin, no lifelong prescriptions.

By Dr. Jeffrey Hockings, Founder, Diabetes Reversal Group.

The only patented system in the world proven to reverse Type 2 diabetes.